• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Mills Kenneth T. was granted 7,768 shares, increasing direct ownership by 2% to 482,871 units (SEC Form 4)

    6/3/25 4:32:36 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGNX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mills Kenneth T.

    (Last) (First) (Middle)
    C/O REGENXBIO INC.
    9804 MEDICAL CENTER DRIVE

    (Street)
    ROCKVILLE MD 20850

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    REGENXBIO Inc. [ RGNX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/30/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/30/2025 A 7,768(1) A $0.00 482,871 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (Right to Buy) $8.85 05/30/2025 A 39,815 (2) 05/30/2035 Common Stock 39,815 $0.00 39,815 D
    Explanation of Responses:
    1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer.
    2. The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer.
    Remarks:
    /s/ Patrick J. Christmas as attorney-in-fact 06/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RGNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RGNX

    DatePrice TargetRatingAnalyst
    2/11/2025$38.00 → $14.00Buy → Neutral
    Goldman
    2/7/2025$27.00Outperform
    Raymond James
    11/15/2024$22.00Overweight
    Morgan Stanley
    10/10/2024$18.00Outperform
    Raymond James
    6/7/2024$38.00Buy
    Goldman
    3/11/2024$36.00Buy
    H.C. Wainwright
    3/8/2024$20.00 → $35.00Sector Perform → Outperform
    RBC Capital Mkts
    3/6/2024$37.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $RGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    REGENXBIO downgraded by Goldman with a new price target

    Goldman downgraded REGENXBIO from Buy to Neutral and set a new price target of $14.00 from $38.00 previously

    2/11/25 7:12:20 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on REGENXBIO with a new price target

    Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $27.00

    2/7/25 8:29:59 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on REGENXBIO with a new price target

    Morgan Stanley resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $22.00

    11/15/24 8:17:57 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    SEC Filings

    View All

    REGENXBIO Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - REGENXBIO Inc. (0001590877) (Filer)

    8/18/25 5:10:27 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by REGENXBIO Inc.

    SCHEDULE 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    8/14/25 4:18:47 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by REGENXBIO Inc.

    10-Q - REGENXBIO Inc. (0001590877) (Filer)

    8/7/25 7:30:55 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

    RGX-121 would be the first and only potential one-time commercially-available therapy designed to directly address the underlying genetic cause of Hunter syndrome, if approvedCommercial launch plans remain on track REGENXBIO plans to present updated pivotal data during the ICIEM meeting in September 2025ROCKVILLE, Md., Aug. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that the U.S. Food and Drug Administration (FDA) extended its review timeline of the Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. The Prescription Drug User Fee Act (PDUFA) goal date has

    8/18/25 5:00:00 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

    RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous guidanceClemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; FDA inspections completed successfullyPre-license inspection (PLI) of in-house manufacturing facility, quality systems and processes completed with no observationsBioresearch monitoring information (BIMO) inspection of laboratory and clinical data practices completed with no observationsSurabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy in chronic retinal dise

    8/7/25 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

    A pivotal Phase IIb/III clinical trial using suprachoroidal delivery for treatment of diabetic retinopathy will be initiatedNew Phase II ALTITUDE® trial data demonstrate a durable safety and efficacy profile observed through two years with a single, in-office injection of surabgene lomparvovec in subjects with non-proliferative diabetic retinopathyREGENXBIO to receive $100 million upon first subject dosed in the Phase IIb/III clinical trial and an additional $100 million upon first subject dosed in a second Phase III clinical trial ROCKVILLE, Md., Aug. 7, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for investigatio

    8/7/25 7:00:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Strategy & Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,699 shares, decreasing direct ownership by 3% to 151,411 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    8/4/25 5:17:06 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Simpson Curran covered exercise/tax liability with 4,701 shares, decreasing direct ownership by 2% to 252,331 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    7/3/25 6:53:52 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Fox Allan M. was granted 7,768 shares, increasing direct ownership by 69% to 19,054 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    6/3/25 4:37:11 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Financials

    Live finance-specific insights

    View All

    REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

    RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous guidanceClemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; FDA inspections completed successfullyPre-license inspection (PLI) of in-house manufacturing facility, quality systems and processes completed with no observationsBioresearch monitoring information (BIMO) inspection of laboratory and clinical data practices completed with no observationsSurabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy in chronic retinal dise

    8/7/25 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

    ROCKVILLE, Md., July 31, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, August 7, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2025, and operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 9571992. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to

    7/31/25 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

    RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H 2025 Initiating commercial supply manufacturing in Q3 2025FDA acceptance of Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121, partnered with Nippon Shinyaku) expected in May 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314, partnered with AbbVie) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study continuesConference call today at 4

    5/12/25 4:05:00 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Leadership Updates

    Live Leadership Updates

    View All

    Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/6/24 6:29:00 PM ET
    $AMTM
    $APO
    $CMA
    Investment Managers
    Finance
    Major Banks
    Apparel

    REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

    Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

    9/17/24 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Leadership Transition

    Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

    6/12/24 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/14/24 9:00:57 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/12/24 4:47:45 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/4/24 1:49:56 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care